Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Shire Plc Ads (SHPG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 53,568,600
  • Shares Outstanding, K 302,340
  • Annual Sales, $ 11,397 M
  • Annual Income, $ 327,400 K
  • 36-Month Beta 1.62
  • Price/Sales 4.90
  • Price/Cash Flow 11.29
  • Price/Book 1.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
175.76 +0.81%
on 04/28/17
192.15 -7.79%
on 05/18/17
+1.43 (+0.81%)
since 04/26/17
3-Month
168.26 +5.30%
on 04/10/17
192.15 -7.79%
on 05/18/17
-4.11 (-2.27%)
since 02/24/17
52-Week
161.09 +9.99%
on 01/23/17
209.22 -15.31%
on 09/20/16
-13.07 (-6.87%)
since 05/26/16

Most Recent Stories

More News
Ultragenyx Receives Priority Review for rhGUS from FDA

The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.

RARE : 55.91 (-4.46%)
VVUS : 1.13 (+0.89%)
BMRN : 88.00 (+0.77%)
SHPG : 177.18 (-4.13%)
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
SHPG : 177.18 (-4.13%)
PFE : 32.14 (-0.06%)
Company News for May 19, 2017

Companies in the News are: LB,P,INCY,MRK,SHPG

P : 9.22 (+0.66%)
LB : 50.51 (+0.48%)
MRK : 64.92 (-0.18%)
INCY : 134.38 (-2.91%)
SHPG : 177.18 (-4.13%)
Blog Coverage: Shire's Stock Price Jumped on Positive Results in Hereditary Angioedema Treatment

Upcoming AWS Coverage on TherapeuticsMD Post-Earnings Results

SHPG : 177.18 (-4.13%)
TXMD : 3.98 (-6.79%)
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

BAYRY : 130.2900 (-0.47%)
JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
LLY : 78.05 (-0.37%)
SHPG : 177.18 (-4.13%)
SNY : 49.00 (-0.06%)
BMY : 53.97 (-0.77%)
The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis

DUBLIN, May 18, 2017 /PRNewswire/ --

SHPG : 177.18 (-4.13%)
PFE : 32.14 (-0.06%)
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

LEXINGTON, Massachusetts, May 18, 2017 /PRNewswire/ --

SHPG : 177.18 (-4.13%)
Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial

-- Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration

SHPG : 177.18 (-4.13%)
Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status

Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.

SGMO : 7.25 (-7.05%)
VVUS : 1.13 (+0.89%)
SHPG : 177.18 (-4.13%)
PFE : 32.14 (-0.06%)
Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association

Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 170th Annual Meeting of the American...

SHPG : 177.18 (-4.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Shire Pharmaceuticals Group plc is a specialty pharmaceutical company focused primarily on two therapeutic areas: central nervous system disorders and metabolic bone diseases. (press release)

See More

Support & Resistance

2nd Resistance Point 182.39
1st Resistance Point 179.78
Last Price 177.18
1st Support Level 175.70
2nd Support Level 174.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.